HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Enti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lili, Hao, Shumin, Gao, Meiling, Liu, Junxiao, Xu, Xin, Huang, Jianfei, Cheng, Genhong, Yang, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155037/
https://www.ncbi.nlm.nih.gov/pubmed/36898011
http://dx.doi.org/10.1158/2326-6066.CIR-22-0317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155037/
https://www.ncbi.nlm.nih.gov/pubmed/36898011
http://dx.doi.org/10.1158/2326-6066.CIR-22-0317

Ejemplares similares